was at an even where someone was infected with covid; have no antibodies for the Covid vaccine; SARS-CoV-2 test, Negative; tingling in fingers and toes; rash came back; using dupixent every 20 or 21 days, went out to 30 (every 30 days); This is a spontaneous report from a contactable consumer or other non hcp (patient) and Other HCP. An 80-year-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot Number: EK9231) on 11Jan2021 (at the age of 80-year-old) at dose 1, 0.3 ml single and received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot Number: EL9265 or EK9265) on 01Feb2021 (at the age of 80-year-old) at dose 2, 0.3 ml single, both the doses via an unspecified route of administration for covid-19 immunisation; dupilumab (DUPIXENT), via an unspecified route of administration from 2017 (Batch/Lot number was not reported) and ongoing, at 300 mg for dermatitis atopic. Medical history included ongoing asthma and atopic dermatitis from an unknown date and unknown if ongoing. Concomitant medications were not reported. Event description: Experienced tingling in fingers and toes, have no antibodies for the covid vaccine, was at an even where some-one was infected with covid, rash came back and using dupixent every 20 or 21 days, went out to 30 (every 30 days) while being treated with DUPILUMAB (DUPIXENT) with the use of medical device not reported and TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE). In 2017, the patient started taking DUPIXENT (DUPILUMAB) (strength: 300 mg) injection at a dose of 600 mg then was prescribed to take 300 mg for every 14 days but patient was taking dose of 300 mg every 30 days or every 20 or 21 days (with an unknown batch number and expiry date) for Atopic dermatitis delivered via unknown device. In the context of COVID19 crisis, the batch number and expiration date were not requested. Therapy date: 2017 to 2017. Dupilumab was not used for the first time. In 2019 the patient developed a non-serious event tingling in fingers and toes (paraesthesla) (un-known latency) following the first dose intake of DUPILUMAB. On 11Jan2021, the patient started taking first dose of PFIZER BIONTECH COVID-19 VACCINE (TOZINAMERAN) at a dose of 0.3 mL (lot EK9231; strength, form, frequency, route, expiry date: unknown) for COVID-19 vaccination and received second dose on 01Feb2021 (batch number. E then L or K then 9265 (EL9265 or EK9265). In Aug2021 the patient developed a non-serious event have no antibodies for the covid vaccine (sars-cov-2 antibody test negative) (unknown latency) following the first dose intake or DUPILUMAB and (unknown latency) following the first dose Intake and (unknown latency) following the last dose intake of TOZINAMERAN. On 01Aug2021 the patient developed a non-serious event was at an even where someone was infected with covid (exposure to sars-cov-2) (unknown latency) following the first dose intake of DUPILUMAB and 6 months 21 days following the first dose intake and 6 months following the last dose intake of TOZINAMERAN. On an unknown date the patient developed a non-serious event rash came back (rash) using dupixent every 20 or 21 days, went out to 30 (every 30 days) (product use issue) (unknown latency) following the first dose intake of DUPI-LUMAB and (unknown latency) following the first dose intake and (unknown latency) following the last dose intake of TOZINAMERAN. It was reported Consumer states that he has been on Dupixent almost 4 years. I had my first Pfizer Covid-19 vaccine on 11Jan2021. I had my second Pfizer Covid-19 vaccine dose on 01Feb2021. My wife had it (Covld-19 vaccines) done the same time. Sunday we were at a wedding. Then we were notified that there was a Covid outbreak, and my wife and I got tested for Covid. I was negative and my wife was negative. Then we got instructions from our doc-tor to get the antibody test. My wife's antibody test was 18 and I have no antibodies for the Covid vaccine. So, I am wondering if I should be getting a booster shot or does DUPIXENT kill the effects of the vaccine because it stops the inflammation. I am taking DUPIXENT for dermatitis, but I think it also works for asthma because I have not had one asthma attack in this period of almost four years that I have been taking DUPIXENT. And I no longer take any asthma medication and it has cleared up my skin. So, it is working for both. So, I am wondering if DUPIXENT caused me not to have anti-bodies to the vaccine and if I am protected against Covid. My job Is that I am an x-ray technician and I take care of patients every day. I think the starter dose was 600 mg and I take 300 mg. I am using it (DUPIXENT) every 20 days. I think it was prescribed for every 14 days. I went out to 30 (every 30 days) but then my rash came back. So, now I am using it (DUPIXENT) every 20 or 21 days and It is controlling my dermatitis. That is how I am using it now. No, I do not have the lot number and expiration date. I am at work now. My doctor is with the Hospital. The lot number for my first Pfizer Covld-19 vaccine of 0.3 mL on 11Jan2021 was EK9231. The lot number for my second Pfizer Covid-19 vaccine of 0.3 mL on 01Feb2021 was E then L or K then 9265 (EL9265 or EK9265). I had called Sandi before because I was having tingling in my fingers and toes and my doctor told me to do that. So, there is correspondence back and forth on that. That was back in Apr2019. I still have that tingling in my fingers and toes but that may be from my age or It may be from this (DUPIXENT). I am slit taking the drug (DUPIXENT). Consumer wants to know is this because of DUPIXENT that stops inflammation could killed the effect of the Covid-19 vaccine. Also wants to know should he get a booster vaccine. Is It possible that he has zero antibodies because his is on DUPIXENT. No further information was provided. Relevant laboratory test results included: SARS-COV-2 antibody test- In Aug2021, 15Aug2021: unknown result no antibodies for the Covid vaccine and SARS-CoV-2 test - In Aug2021: Negative. It was not reported if the patient received a corrective treatment for the events (have no antibodies for the Covid vaccine, using dupixent every 20 or 21 days, went out to 30 (every 30 days), tingling in fingers and toes, was at an even where someone was infected with Covid, rash came back). The action taken in response to the events for dupilumab was dose not changed. At time of reporting, the outcome was not recovered / not resolved for the event have no antibodies for the covid vaccine, unknown for the event using dupixent every 20 or 21 days, went out to 30 (every 30 days), not recovered/, not resolved for the event tingling in fingers and toes, recovered / resolved in aug2021 for the event was at an even where someone was infected with covid and was unknown for the event rash came back, unknown for sars-cov-2 test, negative.   Follow-Up (10Sep2021): Follow-up attempts are completed. No further information is expected.